Skip to content
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Neurology

Living with MMN: Daily Management, Monitoring, and Future Hope

At a Glance

Living with Multifocal Motor Neuropathy (MMN) requires consistent monitoring to prevent permanent nerve damage. By tracking hand-grip strength, utilizing physical and occupational therapy, and exploring clinical trials, patients can successfully manage symptoms and maintain their independence.

Back to Home

Multifocal Motor Neuropathy (MMN) is a chronic condition, meaning it requires long-term attention and management. While it is a progressive disease, it typically moves slowly, and many people live active lives for decades after their diagnosis [1]. The key to a positive long-term outcome is consistent monitoring, proactive treatment, and practical daily management.

Preventing Axonal Loss

The primary clinical goal of MMN treatment is to prevent axonal loss—the permanent death of the nerve fibers [2]. When the immune system attacks the insulation (myelin) of your nerves, the electrical signal is blocked. If the attack continues without treatment, the underlying nerve fiber (the axon) can eventually die [2].

Once an axon is lost, the muscle weakness associated with it often becomes permanent. Research shows that starting treatment early and maintaining a high enough dose of immunoglobulin is critical to preventing this loss and ensuring the best long-term recovery [3][4].

Tools for Monitoring Your Progress

Because MMN changes slowly, it can be hard to notice small shifts in strength or ability. Rather than repeating uncomfortable EMG electrical tests at every visit, doctors use validated tools to track your progress:

  • Hand-Grip Strength: Using a device called a Jamar dynamometer or a Vigorimeter, your doctor can measure the exact pressure your hand can exert [5]. This is one of the most sensitive ways to tell if your treatment is working or if the disease is progressing [6].
  • MMN-RODS: The Multifocal Motor Neuropathy-Rasch-built Overall Disability Scale is a specific questionnaire designed for MMN patients [7]. It asks about your ability to perform daily tasks, such as opening a jar or walking on uneven ground, to measure how the disease affects your real-world life [7].

Managing Daily Life: OT and PT

While IVIg or SCIg targets the underlying disease, practical daily management is essential for preserving your quality of life.

  • Physical Therapy (PT): A targeted PT program can help you maintain flexibility, prevent joint stiffness, and safely keep unaffected muscles strong without overworking damaged nerves [1].
  • Occupational Therapy (OT) and Adaptive Equipment: Because MMN frequently affects the hands and wrists, an occupational therapist is a vital part of your care team. They can fit you for adaptive equipment—such as lightweight wrist splints to help with “drop wrist,” specialized wide grips for pens and utensils, or button-hooks—to help you maintain your independence and conserve energy [1].

Hope for the Future: Emerging Treatments

While immunoglobulin is currently the standard of care, it does not work for everyone, and some patients find its effectiveness fades over time [8]. This has led to exciting research into new types of therapy:

  • Complement Inhibitors: These are a new class of drugs designed to stop the immune system’s attack at a much earlier stage. One such drug, ARGX-117, is currently being studied in clinical trials [9]. It works by blocking a specific protein (C2) in the complement system, preventing the attack on your nerves before it can cause a conduction block [10].
  • Clinical Trials: Many patients choose to participate in trials for these emerging therapies. If your current treatment is not providing the results you need, your doctor can help you explore whether you qualify for these ongoing studies [1].

You do not have to navigate MMN alone. Connecting with rare neuropathy support groups and advocacy organizations can provide immense emotional support and practical advice as you manage this chronic condition over the long term.

Common questions in this guide

How do doctors monitor if my MMN treatment is working?
Doctors track MMN progression using specific tools like a dynamometer to measure hand-grip strength and the MMN-RODS questionnaire. These methods effectively monitor your functional abilities and treatment response without the need for repeated electrical nerve tests.
What is axonal loss in MMN?
Axonal loss refers to the permanent death of a nerve fiber due to ongoing immune system attacks. Preventing this loss is the primary goal of MMN treatment, because once an axon dies, the muscle weakness associated with it usually becomes permanent.
How can occupational therapy help me manage MMN?
An occupational therapist can recommend and fit you with adaptive equipment, such as lightweight wrist splints for drop wrist or wide grips for utensils. This helps you conserve energy, protect your joints, and maintain your independence in daily tasks.
What are complement inhibitors for MMN?
Complement inhibitors are an emerging class of drugs being studied in clinical trials for MMN. They are designed to block specific immune system proteins, aiming to stop the attack on your nerves earlier than current standard treatments.
Why do I feel weaker right before my next treatment?
Many patients notice their strength fluctuates depending on when they received their last immunoglobulin dose, as the medication's effectiveness can fade over time. Keeping a detailed symptom diary helps your neurologist adjust your dosage or treatment schedule to minimize these periods of weakness.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What baseline measurements, such as hand-grip strength, are we recording today to track my progress objectively?
  2. 2.Can we utilize the MMN-RODS questionnaire at every visit to monitor how my functional abilities are changing?
  3. 3.Can you refer me to a physical or occupational therapist who has experience with neuromuscular conditions?
  4. 4.Am I showing signs of 'axonal loss' on my physical exams, and is my current treatment dose high enough to prevent further nerve damage?
  5. 5.How can I find out if I am a candidate for any clinical trials for complement inhibitors like ARGX-117?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Multifocal Motor Neuropathy: A Narrative Review.

    Claytor B, Polston D, Li Y

    Muscle & nerve 2025; (71(4)):512-534 doi:10.1002/mus.28349.

    PMID: 39936246
  2. 2

    Immunoglobulin therapy in the treatment of multifocal motor neuropathy.

    Kumar A, Patwa HS, Nowak RJ

    Journal of the neurological sciences 2017; (375()):190-197 doi:10.1016/j.jns.2017.01.061.

    PMID: 28320129
  3. 3

    A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy.

    Al-Zuhairy A, Sindrup SH, Andersen H, Jakobsen J

    Journal of the peripheral nervous system : JPNS 2019; (24(1)):64-71 doi:10.1111/jns.12311.

    PMID: 30746851
  4. 4

    Prevention of axonal loss after immediate dosage titration of immunoglobulin in multifocal motor neuropathy.

    Al-Zuhairy A, Jakobsen J, Krarup C

    European journal of neurology 2024; (31(7)):e16305 doi:10.1111/ene.16305.

    PMID: 38651498
  5. 5

    Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy.

    Li Z, Roepcke S, Franke R, Yel L

    Annals of clinical and translational neurology 2024; (11(8)):1977-1987 doi:10.1002/acn3.52098.

    PMID: 38978354
  6. 6

    Outcome measures in MMN revisited: further improvement needed.

    Pruppers MH, Draak TH, Vanhoutte EK, et al.

    Journal of the peripheral nervous system : JPNS 2015; (20(3)):306-18 doi:10.1111/jns.12124.

    PMID: 26115442
  7. 7

    Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).

    Vanhoutte EK, Faber CG, van Nes SI, et al.

    Journal of the peripheral nervous system : JPNS 2015; (20(3)):296-305 doi:10.1111/jns.12141.

    PMID: 26329270
  8. 8

    Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment.

    Löscher WN, Oberreiter EM, Erdler M, et al.

    Journal of neurology 2018; (265(12)):2834-2840 doi:10.1007/s00415-018-9071-9.

    PMID: 30259176
  9. 9

    Immunotherapies in chronic immune-mediated neuropathies.

    Briani C, Visentin A

    Handbook of clinical neurology 2026; (214()):345-356 doi:10.1016/B978-0-323-90887-0.00019-5.

    PMID: 41526145
  10. 10

    Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.

    Budding K, Johansen LE, Van de Walle I, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2022; (9(1)) doi:10.1212/NXI.0000000000001107.

    PMID: 34759020

This page provides educational information on managing Multifocal Motor Neuropathy. Always consult your neurologist and physical therapy team before making changes to your treatment or daily management routine.

Get notified when new evidence is published on Multifocal motor neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.